Protecting Pharmaceutical Products from Advanced Development through Commercial Release
June 26, 2019
Webinar
A well-planned patent portfolio is essential in today’s pharmaceutical market as the technological, political, and financial landscapes continue to evolve and impart significant changes in the industry. At one time, the “blockbuster” drug model, where drug companies were targeting diseases affecting large patient populations to achieve high-volume sales, was the norm, but today, we see a focus on research and development dollars going into disease niches. Regardless of whether the product is a “blockbuster” or niche buster, we examine considerations and strategies to protect those innovations, from advanced development to commercial release.
Topics to be discussed include:
- Claiming Strategies (Pre-Clinical, Clinical, Post Marketing)
- Impact and Avoidance of Public Disclosures: Public Use and On Sale Bars
- Orange Book Listing: Coordinating Patent Prosecution and Regulatory Strategies/Submissions
- Litigation Considerations During Portfolio Development and Management
- The Rise of Obviousness in Pharmaceutical Patent Cases
This webinar is the second segment of Finnegan’s 2019 series, “Practical Advice on U.S. Patent Law Issues.” We hope you are able to attend.
Speakers:
Paul W. Browning, Ph.D.
Adriana L. Burgy
Moderator:
Ming-Tao Yang
Date:
Wednesday, June 26, 2019
Time:
7:30 - 8:30 a.m. India
10:00 - 11:00 a.m. China/Taiwan
11:00 a.m. - 12:00 p.m. Japan/Korea
Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.
